WO2023042177 - ENANTIOMERS OF 5-((7-CHLOROISOQUINOLIN-1-YL)AMINO)-N-(6-METHOXY-1,2,3,4-TETRAHYDRONAPHTHALEN-2-YL)PICOLINAMIDE
National phase entry is expected:
Publication Number
WO/2023/042177
Publication Date
23.03.2023
International Application No.
PCT/IB2022/058847
International Filing Date
19.09.2022
Title **
[English]
ENANTIOMERS OF 5-((7-CHLOROISOQUINOLIN-1-YL)AMINO)-N-(6-METHOXY-1,2,3,4-TETRAHYDRONAPHTHALEN-2-YL)PICOLINAMIDE
[French]
ENANTIOMÈRES DU 5-((7-CHLOROISOQUINOLIN-1-YL)AMINO)-N-(6-MÉTHOXY-1,2,3,4-TÉTRAHYDRONAPHTALÈNE-2-YL)PICOLINAMIDE
Applicants **
GT GAIN THERAPEUTICS SA
Via Francesco Soave 6
6900 Lugano, CH
Inventors
GARCÍA COLLAZO, Ana Maria
c/o GAIN THERAPEUTICS SA
Barcelona Science Park
Baldiri Reixac 4-10
08028 Barcelona, ES
MAJ, Roberto
c/o GAIN THERAPEUTICS SA
Via Francesco Soave 6
6900 Lugano, CH
Priority Data
21382846.0
20.09.2021
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1727 | |
| EPO | Filing, Examination | 10575 | |
| Japan | Filing | 595 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 8110 |
Total: 21581 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
, and m are as set forth in the specification, as well as to pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of conditions associated with the alteration of the activity of β-galactosidase, specially galactosidase beta-1 or GLB1, including GM1 gangliosidoses and Morquio syndrome, type B.[French]
et m sont tels que définis dans la description, ainsi que les compositions pharmaceutiques les comprenant, et leur utilisation pour le traitement et/ou la prévention des pathologies associées à l'altération de l'activité de la β-galactosidase, particulièrement la galactosidase bêta-1 ou GLB1, y compris les gangliosidoses GM1 et le syndrome de Morquio, de type B.